icom_donate

Donate Today

icon_get_involved

Get Involved

icon_friend

Friends of

Scientists discover way to stop spread of devastating bone cancer in children

Research, co-funded by Friends of Rosie, could save more lives and lead to kinder treatments for children with bone cancer. Researchers at The University of Manchester and the University of East Anglia and have made what may be the most significant step forward for children with one of the most common childhood cancers in 40 years.

Bone cancer in children, also known as osteosarcoma, is currently treated with a gruelling regime of outdated chemotherapy drugs and often limb amputation. But fewer than half the children survive more than five years. This is largely because bone cancer spreads rapidly around the growing body of a child, particularly to their lungs.

New research published today identifies a set of key genes that cause bone cancer to spread to the lungs. The research was led by Dr Katherine Finegan from The University of Manchester and Dr Darrell Green, from the University of East Anglia’s (UEA) Norwich Medical School.

The work, funded by Friends of Rosie at The University of Manchester, discovered that a protein called, MAPK7, controls the body’s immune response to tumours and by removing it researchers can slow the growth of osteosarcomas and prevent their spread to other parts of the body.

Following the discovery, Dr Katherine Finegan and the Manchester team worked with Dr Darrell Green and his group at the University of East Anglia and together found a potential new way to treat osteosarcoma for the first time in 40 years.

bone cancer research

“If these findings are effective in clinical trials,” said Dr Finegan, “it would no doubt save lives and improve quality of life. The treatment should be much kinder, compared to the gruelling chemotherapy and life changing limb amputation that patients receive today.”

They are already beginning to develop new drugs against MAPK7 to benefit primary bone cancer patients in the future.

The research entitled: Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer, is published in the journal Oncogene on July 13, 2020.

This work has been funded by Friends of Rosie, The Humane Research Trust, Big C, and Paget’s Association.

Super Strong Sophie

One of the patients who donated tissue to the study was five-year-old ‘Super Strong’ Sophie Taylor from Norwich. She was first diagnosed with osteosarcoma in January 2018. She had her leg amputated and months of hard chemotherapy.

Sadly, Sophie was taken to hospital with breathing difficulties a year after diagnosis at the beginning of January 2019, where her family were told there was extensive cancer in her lungs. She passed away on January 18, 2019.

Sophie’s dad, Alex Taylor, said:

“We did not hesitate in offering Sophie’s tumour for research and to also have her DNA and RNA analysed to link it to additional drugs to pursue. It gave us hope. Unfortunately, we did not get to try the potential options for Sophie, but we are extremely pleased that Sophie has been able to help in the way she did.

“Sophie demonstrated strength and courage beyond comprehension and deserved a much better outcome. She fulfilled a range of achievements, including going to the top of Snowdon, playing football and becoming close friends with Leicester City’s James Maddison, and she inspired many people around the world. We are so proud of how she fought and, even more so, that she has contributed to research which will be lifesaving for future children.”

Nancy Dykes

Nancy Dykes

Nancy, 11, was diagnosed with rhabdomyosarcoma when she was just 2 years old. She was treated with Proton Beam Therapy (PBT) in Germany but unfortunately relapsed less than a year later. The family were then sent to Germany for a second round of PBT. Although treatment helped to cure Nancy’s cancer, she has been left with lots of lasting effects which will require ongoing treatment throughout her life. Here Nancy and her mum, Antonia, share their story in the hope it will help others, raise awareness, and raise more money for children’s cancer research.

Prof John Hickman

Prof John Hickman

Why I am a Trustee of CCRF
 
I am a relative of the Larkin family and knew Rosie Larkin ( Friends of Rosie, now CCRF) when she had and then died of neuroblastoma, aged six. At that time, I was a scientist and professor at Manchester University, actively working on the problem of why some cancers do not die despite intensive and toxic therapies.  Seeing Rosie during her unsuccessful therapy and then attending her funeral, besides being emotional, drove me to double down on my own research as well as to support the Charity as best I could as a cancer researcher. I spent over a decade as the Chairman of the Scientific Advisory Board of the CCRF, when the Board moulded policies to ensure that funds raised for research into childhood cancers were distributed only to clinicians and researchers who had the brightest ideas that could impact of cancer medicine for children.
 
My role on the Board
 
As a Trustee,  I hope that my many decades of experience in cancer research and medicine can help the CCRF determine where best the funds that are raised can be invested in cutting edge research and medicine. I am also keen that the CCRF brings together UK and international experts in science and cancer medicine to brainstorm on how best to advance the treatment of childhood cancers.
 
My Background
 
I was a Professor of Pharmacology at Manchester University, working on drug resistance in cancer. I then moved to Paris, where I still live, to head cancer drug discovery at a French pharmaceutical company (Servier). I then headed an EU consortium for six years that brought together researchers from the pharmaceutical industry, universities and biotechnology companies, from all over Europe and the UK, to improve cancer drug discovery. I continue to be active in cancer health policy, publishing in the medical literature.
Katrina

Katrina London

Why I am a Trustee of CCRF

I have spent my professional career representing individuals and families affected by the devastating asbestos-related cancer, mesothelioma, which has no cure and for which there are only a limited number of palliative treatments available on the NHS.

I joined CCRF because I wanted to bring my understanding of the need to raise awareness of less well known cancers and passion for the need to secure improved funding for research to children facing a cancer diagnosis.

My role on the Board

I am responsible for oversight of our collaboration agreements with other charities to co-fund research into cures and treatments for childhood cancers. I also manage our challenge events and help with community fundraising. 

My Background

I am a Senior Associate at Irwin Mitchell LLP and specialise in Asbestos Disease Litigation, acting on behalf of victims of asbestos related diseases and their families.  Over the years, I have undertaken a number of fundraising challenges to raise money for cancer research, including a 1000 mile cycle ride from Glasgow to Southampton.   

Carla

Carla Nuttall

Why I’m a Trustee of CCRF
 
I became a trustee of the Children’s Cancer Research Fund because I believe every child deserves the chance to grow up healthy and with everything to look forward to in life. Like many people, I’ve seen the impact cancer can have on families and I wanted to do something that could make a real difference. This started through my work as an ambassador for Cyclists Fighting Cancer, which supported young people and their families in finding strength, confidence, and joy through movement.
 
That experience shaped my understanding of the challenges families face and the importance of community-led support – but crucially, the clear need for that to go hand-in-hand with targeted research and long-term solutions.
 
This is why I’m so passionate about the work CCRF does and proud to contribute to a cause that gives children and their families, the greatest chance of living a life without limits.
 
My Role on the Board
 
I support CCRF’s mission by bringing my experience in brand, marketing, and communications to the board. My focus is on helping CCRF tell its story in a way that resonates with people – whether that’s families, researchers, donors, or the wider public. I work alongside an incredible team to strengthen CCRF’s voice, build trust, and grow awareness so that more children and families can benefit from the breakthroughs we’re helping to fund.
 
My Background
 
I’m the Executive Director of Corporate Affairs and Marketing for The Growth Company, a social enterprise dedicated to helping people, businesses, and places to thrive through its market-leading insight, employment, skills and business support.
My passion is to help the organisations I work with to communicate with clarity, purpose, and integrity. That’s why I’ve spent my career in strategic communications supporting organisations that want to make a positive difference – CCRF could not fit my sense of purpose any better.